PPARG and Cirrhosis: TZDs also can activate AMP‐activated protein kinase (AMPK) and reduce hepatic fat content.25 TZD use can increase adiponectin and reduce high‐sensitivity C‐reactive protein (hs‐CRP), TNFα, IL‐1β and IL‐6 levels, which can reduce hepatic inflammation.26, 27 In preclinical studies, TZDs bind to PPARγ and thus inhibit the activation of hepatic stellate cells, reduce extracellular matrix production, decrease transforming growth factor β1 expression, attenuate matrix remodelling, and protect for tissue repair, fibrosis and even cirrhosis.28